Skip to main content

Table 4 Comparison of general AEs for dabrafenib plus trametinib versus vemurafenib plus cobimetinib

From: Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

  Incidence, number (%) ITC results
COMBI-v coBRIM
AE type D + T (n = 350) V (n = 349) V (n = 246) V + C (n = 247) RR LCI UCI p value
Any AE 345(98.6) 345(98.9) 240(97.6) 244(98.8) 0.98 0.96 1.01 0.3078
Any serious AE 151(43.1) 136(39.0) 64(26.0) 85(34.4) 0.84 0.60 1.16 0.2835
Any treatment-related AE 320(91.4) 342(98.0) 232(94.3) 237(96.0) 0.92 0.87 0.97 0.0015
AE leading to death 4(1.1) 4(1.2) 3(1.2) 5(2.0) 0.60 0.08 4.35 0.6137
Any grade ≥3 AE 199 (56.9) 232 (66.5) 146 (59.4) 176 (71.3) 0.71 0.60 0.85 0.0002
Any dose interruptions/modifications 192(54.9) 197(56.5) 87(35.4) 110(44.5) 0.77 0.60 1.00 0.0471
Discontinuation due to AE 55(15.7) 48(13.8) 20(8.1) 37(15.0) 0.62 0.33 1.16 0.1350
  1. AE adverse event, CI confidence interval, D + T dabrafenib plus trametinib, ITC indirect treatment comparison, RR risk ratio, LCI lower 95% CI, UCI upper 95% CI, V vemurafenib, V + C vemurafenib plus cobimetinib